{"created":"2023-07-25T10:25:16.802550+00:00","id":5521,"links":{},"metadata":{"_buckets":{"deposit":"ef684493-4230-4cec-a97f-38dd21bdccc4"},"_deposit":{"created_by":15,"id":"5521","owners":[15],"pid":{"revision_id":0,"type":"depid","value":"5521"},"status":"published"},"_oai":{"id":"oai:air.repo.nii.ac.jp:00005521","sets":["611:939:940","920:921:922"]},"author_link":["15555","15556","15557","14974","15558","15559","15560","5587","10096","8893"],"control_number":"5521","item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageStart":"882","bibliographicVolumeNumber":"19","bibliographic_titles":[{"bibliographic_title":"International Journal of Molecular Sciences"}]}]},"item_10001_description_5":{"attribute_name":"内容記述（抄録）","attribute_value_mlt":[{"subitem_description":"While tacrolimus and everolimus have common metabolic pathways through CYP3A4/5, tacrolimus is metabolized solely by CYP3A4 in recipients with the CYP3A5*3/*3. The purpose of this study was to evaluate how the area under the blood concentration-time curves (AUC) of tacrolimus could be predicted based on CYP3A5 genotype and the AUC of everolimus in renal transplant patients taking both drugs. The dose-adjusted AUC (AUC/D) of tacrolimus and everolimus were calculated at one month and one year after transplantation. Significant correlations between the AUC/D of tacrolimus and everolimus were found for patients with the CYP3A5*1 allele or CYP3A5*3/*3 at both one month and one year. At both stages, the determination coefficients were higher and the slopes of regression equations were larger for patients with CYP3A5*3/*3 compared to the CYP3A5*1 allele. A good correlation between single doses of tacrolimus and everolimus was found for CYP3A5*3/*3 patients at 1 year after transplantation (r = 0.794, p < 0.001). The variability of the AUC0–24/D of tacrolimus for each CYP3A5 genotype could be predicted based on the AUC0–12/D of everolimus. Clinicians may be able to comprehensively carry out the dose adjustments of tacrolimus and everolimus based on relationship with AUCs of both drugs in each CYP3A5 genotype.","subitem_description_type":"Other"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"MDPI"}]},"item_10001_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.3390/ijms19030882","subitem_relation_type_select":"DOI"}}]},"item_10001_relation_25":{"attribute_name":"関連リンク","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.3390/ijms19030882","subitem_relation_type_select":"DOI"}}]},"item_10001_rights_15":{"attribute_name":"著作権等","attribute_value_mlt":[{"subitem_rights":"© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)."}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1422-0067","subitem_source_identifier_type":"ISSN"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Kagaya, Hideaki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Niioka, Takenori"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Saito, Mitsuru"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Inoue, Takamitsu"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Numakura, Kazuyuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yamamoto, Ryohei"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Akamine, Yumiko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"HABUCHI, Tomonori"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"SATOH, Shigeru"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Miura, Masatomo"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-11-25"}],"displaytype":"detail","filename":"byoA_2021_2.pdf","filesize":[{"value":"1.3 MB"}],"format":"application/pdf","license_note":"CC BY 4.0","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"byoA_2021_2","url":"https://air.repo.nii.ac.jp/record/5521/files/byoA_2021_2.pdf"},"version_id":"bacde3c1-e7b8-498d-a372-496f9d18a981"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"tacrolimus","subitem_subject_scheme":"Other"},{"subitem_subject":"everolimus","subitem_subject_scheme":"Other"},{"subitem_subject":"CYP3A5 polymorphism","subitem_subject_scheme":"Other"},{"subitem_subject":"renal transplantation","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"15","path":["940","922"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2021-11-25"},"publish_date":"2021-11-25","publish_status":"0","recid":"5521","relation_version_is_last":true,"title":["Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients"],"weko_creator_id":"15","weko_shared_id":-1},"updated":"2024-04-01T07:46:15.534948+00:00"}